New drugs for the treatment of coronary artery syndromes: otamixaban and ticagrelor

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.11, Iss.2, 2010-02, pp. : 325-329

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Review of ticagrelor in the management of acute coronary syndromes

By Burgess Sonya Mallard Trevor A Juergens Craig P

Expert Opinion on Drug Metabolism and Toxicology, Vol. 8, Iss. 10, 2012-10 ,pp. : 1315-1325

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of ticagrelor in acute coronary syndromes

By Henriksson Martin Janzon Magnus

Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 13, Iss. 1, 2013-02 ,pp. : 9-18

Informa Healthcare

Access to resources Recommend Favorite

Ticagrelor: A Review of its Use in the Management of Acute Coronary Syndromes

By Deeks Emma D.

Drugs, Vol. 71, Iss. 7, 2011-05 ,pp. : 909-933

Adis International

Access to resources Recommend Favorite

Ticagrelor: a guide to its use in the management of acute coronary syndromes

By Scott Lesley J. Deeks Emma D.

Drugs & Therapy Perspectives, Vol. 28, Iss. 1, 2012-01 ,pp. : 1-5

Adis International

Access to resources Recommend Favorite

Immunomodulatory Drugs (IMiDs™): A New Treatment Option for Myelodysplastic Syndromes

Current Pharmaceutical Biotechnology, Vol. 7, Iss. 5, 2006-10 ,pp. : 339-342

Bentham Science Publishers

Access to resources Recommend Favorite